News

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

  • Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes
    06/20/2024

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

  • Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy
    06/13/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

GlucoTrack, Inc. (GCTK) can sell. Click on Rating Page for detail.

The price of GlucoTrack, Inc. (GCTK) is 1.36 and it was updated on 2024-07-27 07:01:07.

Currently GlucoTrack, Inc. (GCTK) is in undervalued.

News
    
News

GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE

  • Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference.
    Mon, Jun. 10, 2024

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

  • Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90
    Wed, Jun. 05, 2024

GLUCOTRACK'S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY

  • Promising results support the potential of epidural glucose monitoring for simplified disease management for patients with painful diabetic neuropathy
    Thu, May. 16, 2024

GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

  • 1-for-5 reverse stock split to become effective as of the opening of trading on May 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK”.
    Wed, May. 15, 2024

GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

  • Continuous blood glucose monitor's preclinical data and sensor longevity modeling to be presented at major diabetes conference
    Thu, May. 02, 2024
SEC Filings
SEC Filings

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 07/03/2024

GlucoTrack, Inc. (GCTK) - D

  • SEC Filings
  • 05/08/2024

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 04/24/2024

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 04/24/2024

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 04/01/2024

GlucoTrack, Inc. (GCTK) - PRE 14A

  • SEC Filings
  • 03/22/2024

GlucoTrack, Inc. (GCTK) - SC 13G

  • SEC Filings
  • 01/03/2024

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 10/18/2023

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 09/11/2023

GlucoTrack, Inc. (GCTK) - 424B5

  • SEC Filings
  • 04/17/2023

GlucoTrack, Inc. (GCTK) - 424B5

  • SEC Filings
  • 04/13/2023

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 03/02/2023

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 08/10/2022

GlucoTrack, Inc. (GCTK) - CERT

  • SEC Filings
  • 12/09/2021

GlucoTrack, Inc. (GCTK) - 8-A12B

  • SEC Filings
  • 12/08/2021

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 09/28/2021

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 09/27/2021

GlucoTrack, Inc. (GCTK) - UPLOAD

  • SEC Filings
  • 09/23/2021

GlucoTrack, Inc. (GCTK) - CORRESP

  • SEC Filings
  • 09/23/2021

GlucoTrack, Inc. (GCTK) - S-3

  • SEC Filings
  • 09/20/2021

GlucoTrack, Inc. (GCTK) - D

  • SEC Filings
  • 02/28/2020

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 02/26/2020

GlucoTrack, Inc. (GCTK) - SC 13D

  • SEC Filings
  • 02/25/2020

GlucoTrack, Inc. (GCTK) - PRE 14A

  • SEC Filings
  • 02/11/2020

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 08/14/2019

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 07/19/2019

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 11/23/2018

GlucoTrack, Inc. (GCTK) - PRE 14A

  • SEC Filings
  • 11/13/2018

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 08/20/2018

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 07/02/2018

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 07/02/2018

GlucoTrack, Inc. (GCTK) - POS AM

  • SEC Filings
  • 06/07/2018

GlucoTrack, Inc. (GCTK) - DEFA14A

  • SEC Filings
  • 03/06/2018

GlucoTrack, Inc. (GCTK) - DEFR14A

  • SEC Filings
  • 03/02/2018

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 03/01/2018

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 12/27/2017

GlucoTrack, Inc. (GCTK) - S-1/A

  • SEC Filings
  • 12/21/2017

GlucoTrack, Inc. (GCTK) - CORRESP

  • SEC Filings
  • 12/21/2017

GlucoTrack, Inc. (GCTK) - D

  • SEC Filings
  • 12/11/2017

GlucoTrack, Inc. (GCTK) - S-1/A

  • SEC Filings
  • 12/08/2017

GlucoTrack, Inc. (GCTK) - CORRESP

  • SEC Filings
  • 12/08/2017

GlucoTrack, Inc. (GCTK) - UPLOAD

  • SEC Filings
  • 11/29/2017

GlucoTrack, Inc. (GCTK) - S-1

  • SEC Filings
  • 11/07/2017

GlucoTrack, Inc. (GCTK) - D/A

  • SEC Filings
  • 06/28/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 06/28/2017

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 06/28/2017

GlucoTrack, Inc. (GCTK) - 4/A

  • SEC Filings
  • 06/09/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 06/09/2017

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 06/08/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 06/07/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 06/06/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 04/14/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 03/22/2017

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 03/22/2017

GlucoTrack, Inc. (GCTK) - SC 13G

  • SEC Filings
  • 03/20/2017

GlucoTrack, Inc. (GCTK) - SC 13D/A

  • SEC Filings
  • 03/15/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 03/14/2017

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 02/09/2017

GlucoTrack, Inc. (GCTK) - D/A

  • SEC Filings
  • 01/20/2017

GlucoTrack, Inc. (GCTK) - SC 13D

  • SEC Filings
  • 01/13/2017

GlucoTrack, Inc. (GCTK) - 3/A

  • SEC Filings
  • 01/13/2017

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 12/02/2016

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 11/21/2016

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 11/21/2016

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 11/15/2016

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 11/15/2016

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 07/19/2016

GlucoTrack, Inc. (GCTK) - POS AM

  • SEC Filings
  • 06/22/2016

GlucoTrack, Inc. (GCTK) - S-8

  • SEC Filings
  • 06/15/2016

GlucoTrack, Inc. (GCTK) - SD

  • SEC Filings
  • 05/31/2016

GlucoTrack, Inc. (GCTK) - D

  • SEC Filings
  • 04/18/2016

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 03/25/2016

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 03/25/2016

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 03/21/2016

GlucoTrack, Inc. (GCTK) - SC 13G/A

  • SEC Filings
  • 02/16/2016

GlucoTrack, Inc. (GCTK) - S-8

  • SEC Filings
  • 09/21/2015

GlucoTrack, Inc. (GCTK) - DEFA14A

  • SEC Filings
  • 07/22/2015

GlucoTrack, Inc. (GCTK) - DEFA14A

  • SEC Filings
  • 06/05/2015

GlucoTrack, Inc. (GCTK) - SD

  • SEC Filings
  • 06/01/2015

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 05/19/2015

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 04/30/2015

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 04/30/2015

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 04/22/2015

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 04/16/2015

GlucoTrack, Inc. (GCTK) - S-1

  • SEC Filings
  • 03/31/2015

GlucoTrack, Inc. (GCTK) - 4

  • SEC Filings
  • 03/13/2015

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 11/20/2014

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 10/16/2014

GlucoTrack, Inc. (GCTK) - D

  • SEC Filings
  • 09/12/2014

GlucoTrack, Inc. (GCTK) - DEFA14A

  • SEC Filings
  • 07/09/2014

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 05/05/2014

GlucoTrack, Inc. (GCTK) - DEFA14A

  • SEC Filings
  • 05/05/2014

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 05/05/2014

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 04/30/2014

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 04/29/2014

GlucoTrack, Inc. (GCTK) - POS AM

  • SEC Filings
  • 03/28/2014

GlucoTrack, Inc. (GCTK) - SC 13G/A

  • SEC Filings
  • 02/12/2014

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 05/15/2013

GlucoTrack, Inc. (GCTK) - 424B3

  • SEC Filings
  • 05/15/2013

GlucoTrack, Inc. (GCTK) - S-1/A

  • SEC Filings
  • 05/14/2013

GlucoTrack, Inc. (GCTK) - S-1/A

  • SEC Filings
  • 05/13/2013

GlucoTrack, Inc. (GCTK) - DEF 14A

  • SEC Filings
  • 04/30/2013

GlucoTrack, Inc. (GCTK) - S-1

  • SEC Filings
  • 04/29/2013

GlucoTrack, Inc. (GCTK) - ARS

  • SEC Filings
  • 04/29/2013

GlucoTrack, Inc. (GCTK) - D/A

  • SEC Filings
  • 03/28/2013

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 03/12/2013

GlucoTrack, Inc. (GCTK) - SC 13G

  • SEC Filings
  • 02/14/2013

GlucoTrack, Inc. (GCTK) - RW

  • SEC Filings
  • 01/16/2013

GlucoTrack, Inc. (GCTK) - D

  • SEC Filings
  • 12/03/2012

GlucoTrack, Inc. (GCTK) - POS AM

  • SEC Filings
  • 09/28/2012

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 08/28/2012

GlucoTrack, Inc. (GCTK) - 3

  • SEC Filings
  • 08/24/2012

GlucoTrack, Inc. (GCTK) - 8-A12G

  • SEC Filings
  • 08/14/2012

GlucoTrack, Inc. (GCTK) - EFFECT

  • SEC Filings
  • 11/15/2011

GlucoTrack, Inc. (GCTK) - UPLOAD

  • SEC Filings
  • 11/10/2011

GlucoTrack, Inc. (GCTK) - S-1/A

  • SEC Filings
  • 11/10/2011

GlucoTrack, Inc. (GCTK) - CORRESP

  • SEC Filings
  • 11/10/2011

GlucoTrack, Inc. (GCTK) - S-1/A

  • SEC Filings
  • 10/27/2011

GlucoTrack, Inc. (GCTK) - CORRESP

  • SEC Filings
  • 10/26/2011

GlucoTrack, Inc. (GCTK) - UPLOAD

  • SEC Filings
  • 10/24/2011

GlucoTrack, Inc. (GCTK) - S-1/A

  • SEC Filings
  • 10/07/2011

GlucoTrack, Inc. (GCTK) - CORRESP

  • SEC Filings
  • 10/07/2011

GlucoTrack, Inc. (GCTK) - UPLOAD

  • SEC Filings
  • 09/16/2011

GlucoTrack, Inc. (GCTK) - S-1

  • SEC Filings
  • 08/22/2011

GlucoTrack, Inc. (GCTK) - D

  • SEC Filings
  • 12/27/2010
Press Releases
StockPrice Release
More Headlines
News

GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT

  • Rutherford, NJ, April 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that the Company has closed a private placement of securities. The Offering included participation by CEO Paul V. Goode, PhD, as well as other members of the Company's executive management, Board of Directors, and existing shareholders.
  • 04/22/2024

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

  • Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy
  • 04/16/2024

GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

  • Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced
  • 04/02/2024

GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY

  • Rutherford, NJ, March 12, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Vincent Wong has joined the Company as Vice President of Quality.
  • 03/12/2024

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

  • Rutherford, NJ & Brooklyn Park, MN, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the selection of Cirtec Medical Corp, the leading medical device solutions provider of implantable therapies, as manufacturer for the implantable Continuous Blood Glucose Monitor (CBGM). The two companies have signed a development agreement for clinical and commercial manufacturing.
  • 02/27/2024

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

  • Rutherford, NJ, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes announced today that Luis Malavé has been elected as Chairman of its Board of Directors, effective immediately.
  • 02/13/2024

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

  • Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, provides, updates on initial and long-term preclinical testing for the implantable Continuous Blood Glucose Monitor™ (CBGM).
  • 01/02/2024

GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

  • Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until May 20, 2024, to regain compliance with Nasdaq's minimum bid price rule.
  • 11/30/2023

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

  • Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.
  • 11/13/2023

GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

  • Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing.
  • 10/12/2023

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS

  • Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately.
  • 08/31/2023

GLUCOTRACK ANNOUNCES NEW VP OF MARKETING

  • Rutherford, NJ, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Drinda Benjamin has joined the company as Vice President of Marketing.
  • 08/28/2023

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

  • Rutherford, NJ, July 25, 2023 (GLOBE NEWSWIRE) -- - Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes.
  • 07/25/2023

Why Is GlucoTrack (GCTK) Stock Down 36% Today?

  • GlucoTrack (NASDAQ: GCTK ) stock is falling on Thursday after the medical device company revealed plans for a proposed public stock offering. According to a news release from the company, it's planning for a firm commitment underwritten public offering.
  • 04/13/2023

Spotting Winning Penny Stocks: 3 Top Tips

  • Can these tips help you make money with penny stocks in 2023? The post Spotting Winning Penny Stocks: 3 Top Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 04/11/2023
Unlock
GCTK Ratings Summary
GCTK Quant Ranking